Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 292-642-5 | CAS number: 90669-48-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Physical-chemical properties and results of in vivo studies using very similar materials suggest that oral absorption of the substance will be extremely limited, and even more limited or absent following dermal exposure. For risk assessment purposes the substance will be assumed to be absorbed at 2% after oral and dermal exposure. In absence of any data and as a worst-case assumption, for risk assessment purposes absorption by inhalation will be assumed to be 100%.
Distribution within the body would be also limited, mainly to the liver, fat, and kidney and adipose tissues. On the basis of similarity to mineral oil (paraffin oils), the substance could also reach the spleen, but the high molecular weight means distribution to the brain is unlikely, (in contrast to the mineral oils). Protein binding would possibly play a major role in distribution of the registered substance, as the accumulation of alpha2-microglobulin in the kidney of male rats treated with a structurally-related substance appears to suggest.
It is likely that the substance will be used as a source of energy, and subjected to β-oxidation like fatty acids, but beginning within peroxisomes because of the length of the side-chain. Conjugation of final products and/or simplest components is likely to occur, allowing excretion in urine.
Given its lipophilic nature, accumulation of absorbed components in adipose tissue cannot be excluded, although there was no evidence of accumulation or of any adverse effects.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 2
- Absorption rate - dermal (%):
- 2
- Absorption rate - inhalation (%):
- 100
Additional information
Introduction
There are no experimental toxicokinetic studies available on the substance. Thus, physical-chemical properties and the results of in vitro studies and in vivo acute or repeat dose toxicity studies on the substance, or structurally related substance(s), have been used to estimate a toxicokinetic profile.
Physicochemical properties
The substance is an “Unknown or Variable Composition, Complex (UVCB) reaction product”. The substance is manufactured by the esterification of the starting material, hydrocarbon waxes (petroleum) oxidized, with butanol. This reaction takes place at ambient pressure and elevated temperatures at levels approaching 110°C for several hours. The resulting substance is brown solid/paste. It is poorly water soluble ( 5.31 - 69.8 mg/L at 20.0 ± 0.5 °C) with a log Pow value assumed to be greater than 9.4 (from read across data). The vapour pressure of the substance is < 1 Pa at 25 ºC. Typical carbon lengths are considered to be in the region of C20-C50.
Absorption
Oral absorption
The main physical chemical properties that influence absorption are molecular weight, water solubility and lipid solubility. The high molecular weight, high log Pow value, together with the low water solubility suggest very limited oral absorption. It is worthy to note that due to the intended use of substance, oral exposure in humans would only occur as an accident or in cases of deliberate misuse.
Public available data (EFSA Scientific Report, 2008; IPCS WHO Food Additive Series No. 5 – Food-grade mineral oil, 1974) on the structurally-related substances mineral oils (paraffin oil, CAS # 64742-46-7, 72623-86-0 and 97862-82-3) indicate that these are biochemically inert chemical substances, especially the straight chain (n) alkanes, and on ingestion most of the mineral oil (98%) remains unabsorbed in the faeces. This is the reason why sources of mineral oil are laxative in pharmacy. Small amounts of mineral oil (2%) are absorbed by the intestinal mucosa and are distributed throughout the body. A very small fraction may undergo further biochemical transformation. This value was confirmed in in vivo studies using H3-labelled mineral oil. Europe (EFSA) accepted a value of 2% for mineral oil absorption in 2008.
Minimal oral absorption appears to be even more applicable to the registered substance, which is a waxy solid instead of a liquid, and this is supported by the results of in vivo toxicological studies, using either the registered substance or a structurally-related substance (Distillates (petroleum), oxidized light, CAS # 64742-98-9). The acute oral LD50 for the registered substance was determined to be greater than 2000 mg/kg and the repeat-dose NOAEL, determined for the structurally-related substance, was at the limit dose of 1000 mg/kg/day. No signs of systemic toxicity were observed in the acute oral study, and observations in animals treated at 1000 mg/kg/day with the structurally-related substance were limited to salivation after dosing, commonly observable when an irritating substance is administered by gavage. There were no necropsy findings and no toxicologically significant changes in organ weights in the repeat-dose OECD 422 study, although histopathology detected changes in kidney (in males), thyroid and stomach, mainly adaptive in nature but offering evidence that some absorption had occurred. While the changes in the stomach (i.e., minimal acanthosis, occasionally associated with hyperkeratosis) were a portal-of-entry effect, once again indicative of adaptive changes related to administration of a highly concentrated epithelial irritant, those in kidney of males (i.e., globular accumulations of eosinophilic material in the tubular epithelium, consistent with accumulation of alpha2-microglobulin) and in the thyroid (i.e., minimal to slight follicular cell hypertrophy), accompanied by relative liver weight increase, indicated that part of the administered substance has been absorbed, distributed or transported within the body and had stimulated the liver for its metabolism.
For risk assessment purposes the worst-case oral absorption of the substance will be assumed to be 2% based on similarity to paraffin oil.
Dermal absorption
The physical state, high molecular weight, high log Pow value, together with the low water solubility indicate very low potential for dermal absorption. Similarly to mineral oils, deposition in the stratum corneum is expected to occur slowly; however, the substance is not sufficiently water soluble to partition from the stratum corneum into the epidermis.
As dermal absorption cannot be greater than oral absorption, and the estimate of 2% oral absorption is already a worst-case estimate, no dermal absorption of the registered substance is expected to occur.
However, just for risk assessment purposes the same rate of oral absorption (2%) with be used for dermal absorption in order to set dermal (systemic) DNELs.
Inhalation absorption
The registered substance has low vapour pressure and therefore is unlikely to be available for inhalation as a vapour. The low water solubility and high molecular weight and log Pow value suggest a limited absorption after inhalation. If any amount of the substance reaches the alveoli, this will be likely phagocytised by macrophages, located into the immune surveillance tissues and broken down in lysososmes and peroxisomes.
In absence of any data, and as a worst-case assumption, for risk assessment purposes absorption by inhalation will be assumed to be 100%.
Distribution
Distribution within the body appears to be limited by the high molecular weight and low water solubility however, the high log Pow value suggests a higher concentration inside the cells, especially those of fatty and adipose tissues, rather than in the extracellular compartment. Data for food-grade mineral oil (IPCS WHO Food Additive Series No. 5 – Food-grade mineral oil, 1974) indicate that oil droplets, identified as saturated alkane hydrocarbons, have been demonstrated in mesenteric lymph nodes and nodes of the porta hepatis in man. Similar droplets have been identified in human liver, spleen and adipose tissue, consistent with the calculated intake from food use, but no known harm appears associated with these residues. Similar deposition of oil and minor absorption was demonstrated in rabbits, rats and guinea pigs fed liquid petrolatum for 7 months or more. Histochemical evidence showed absorption to be proportionate to length of exposure. The mechanism of absorption was unknown but the absorbed particles showed evidence of foreign body reaction and phagocytic ingestion. No similar findings were noted in the OECD 422 study performed with the structurally-related substance however, the increased accumulation of alpha2-microglobulin in the kidney of male rats suggests that protein binding could have contributed to distribution within the body. The increased relative liver weight and consequent adaptive changes in the thyroid observed at 1000 mg/kg/day in the same OECD 422 study also support that the substance reached the liver, there stimulating its own metabolism.
Metabolism
Available data on the structurally-related substance mineral oil indicated that the biochemical transformation of paraffin may involve hydroxylation via cytochrome P450 mono-oxygenase to the respective alcohol and then further oxidation to carboxylic acids and CO2or solubilisation by building a glucuronide.
The registered substance consists of mono- and di-carboxylic acids, oxyacids, aldehydes, and ketones. It is likely that metabolism of largest components will be slow, involving β-oxidation of the side-chain, which will start within peroxisomes instead of mitochondria, because of the length of the side chain, and produce energy and hydrogen peroxide which would be used to oxidize other substances. It is expected that the terminal metabolites obtained either after the side chain has been metabolized or by metabolism of simplest components, can be conjugated and excreted.
Elimination
The high molecular weight and low water solubility suggest that main elimination of the almost unchanged substance will be via the faeces. Excretion of the limited absorbed amount will be again mainly in faeces via the bile, with urinary excretion limited to conjugates.
Conclusion
Physical-chemical properties and results of in vivo studies using very similar materials suggest that oral absorption of the substance will be extremely limited, and even more limited or absent following dermal exposure. For risk assessment purposes the substance will be assumed to be absorbed at 2% after oral and dermal exposure. In absence of any data and as a worst-case assumption, for risk assessment purposes absorption by inhalation will be assumed to be 100%.
Distribution within the body would be also limited, mainly to the liver, fat, and kidney and adipose tissues. On the basis of similarity to mineral oil (paraffin oils), the substance could also reach the spleen, but the high molecular weight means distribution to the brain is unlikely, (in contrast to the mineral oils). Protein binding would possibly play a major role in distribution of the registered substance, as the accumulation of alpha2-microglobulin in the kidney of male rats treated with a structurally-related substance appears to suggest.
It is likely that the substance will be used as a source of energy, and subjected to β-oxidation like fatty acids, but beginning within peroxisomes because of the length of the side-chain. Conjugation of final products and/or simplest components is likely to occur, allowing excretion in urine.
Given its lipophilic nature, accumulation of absorbed components in adipose tissue cannot be excluded, although there was no evidence of accumulation or of any adverse effects.
References
EFSA (2008)
Conclusion on pesticide peer review regarding the risk assessment of the active substance paraffin oils (CAS 64742-46-7, 72623-86-0 and 97862-82-3).
EFSA Scientific Report (2008) 216, 1-59
Published
Anonymous ICPS (1974)
WHO Food Additive Series No. 5 – Food-grade mineral oil
The International Programme on Chemical Safety (IPCS)
Published
Kuthy P.M. (2012)
Acute Oral Toxicity Study (Acute Toxic Class Method) of Test Item Aphanox 2015 in Rats (Batch # 00312/00347)
Toxi-Coop Zrt., project No. 732.321.3867
GLP
Unpublished
Dhinsa N.K., McKenzie J. & Brooks P.N. (2005) OS 164316B: Oral gavage combined repeat dose toxicity study with reproduction/developmental toxicity screening test in the rat
Safepharm Laboratories Limited project No. 525/575
GLP
Unpublished
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.